• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis.中东欧炎症性肠病护理中的障碍:一项区域特异性分析。
Therap Adv Gastroenterol. 2023 Jun 12;16:17562848231174290. doi: 10.1177/17562848231174290. eCollection 2023.
2
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.炎症性肠病的生物治疗:中东欧地区的可及性
World J Gastroenterol. 2015 Feb 14;21(6):1728-37. doi: 10.3748/wjg.v21.i6.1728.
3
Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.克罗恩病和溃疡性结肠炎。欧洲一项基于人群的起始队列研究中疾病第一年的发病率、病程及预后
Dan Med J. 2014 Jan;61(1):B4778.
4
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响:直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
5
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.在一项基于人群的研究中,在 5 年的随访期间,对泛欧社区为基础的炎症性肠病发病队列进行了医疗成本分析。
Lancet Gastroenterol Hepatol. 2020 May;5(5):454-464. doi: 10.1016/S2468-1253(20)30012-1. Epub 2020 Feb 13.
6
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.《2018年炎症性肠病在加拿大的影响:患有炎症性肠病的儿童和青少年》
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
7
Perspectives of IBD China: Is Crohn's and Colitis Foundation Model a Solution to Health Care Issues for the Country?IBD 中国视角:克罗恩病和结肠炎基金会模式是否为国家医疗保健问题提供了一个解决方案?
Inflamm Bowel Dis. 2018 Apr 23;24(5):925-929. doi: 10.1093/ibd/izy056.
8
Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?东欧炎症性肠病的发病率和患病率在上升吗?
Postgrad Med J. 2006 May;82(967):332-7. doi: 10.1136/pgmj.2005.042416.
9
Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement.中东欧和波罗的海地区的心力衰竭护理:现状、障碍和改善途径。
ESC Heart Fail. 2024 Aug;11(4):1861-1874. doi: 10.1002/ehf2.14687. Epub 2024 Mar 22.
10
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率:基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.

本文引用的文献

1
Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.Meta 分析:抗 TNF 治疗炎症性肠病的治疗药物监测的疗效。
Aliment Pharmacol Ther. 2023 Jun;57(12):1362-1374. doi: 10.1111/apt.17313. Epub 2022 Dec 9.
2
Epidemiology, Treatment Strategy, Natural Disease Course and Surgical Outcomes of Patients with Ulcerative Colitis in Western Hungary - A Population-based Study Between 2007 and 2018: Data from the Veszprem County Cohort.匈牙利西部溃疡性结肠炎患者的流行病学、治疗策略、自然病程及手术结果——基于2007年至2018年韦伦采县队列的人群研究
J Crohns Colitis. 2023 Apr 3;17(3):352-360. doi: 10.1093/ecco-jcc/jjac142.
3
Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn's Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018.匈牙利西部维斯普雷姆队列中克罗恩病患者的发病率、患病率、疾病进程及治疗策略:一项基于人群的2007年至2018年起始队列研究
J Crohns Colitis. 2023 Mar 18;17(2):240-248. doi: 10.1093/ecco-jcc/jjac132.
4
Nationwide data on epidemiology of inflammatory bowel disease in Poland between 2009 and 2020.波兰 2009 年至 2020 年炎症性肠病流行病学的全国性数据。
Pol Arch Intern Med. 2022 May 30;132(5). doi: 10.20452/pamw.16194. Epub 2022 Jan 19.
5
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.欧洲克罗恩病和结肠炎组织(ECCO)溃疡性结肠炎治疗指南:药物治疗
J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178.
6
Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management.改善炎症性肠病(IBD)患者的护理:IBD 中心管理的观点和策略。
Korean J Intern Med. 2021 Sep;36(5):1040-1048. doi: 10.3904/kjim.2021.114. Epub 2021 Aug 5.
7
Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study.超声引导下对不同生物治疗方案的克罗恩病进行紧密控制和监测:一项多中心研究。
Clin Gastroenterol Hepatol. 2022 Apr;20(4):e711-e722. doi: 10.1016/j.cgh.2021.03.030. Epub 2021 Mar 26.
8
The Burden of Inflammatory Bowel Disease in Europe in 2020.2020 年欧洲炎症性肠病负担
J Crohns Colitis. 2021 Sep 25;15(9):1573-1587. doi: 10.1093/ecco-jcc/jjab029.
9
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.STRIDE-II:炎症性肠病(STRIDE)国际研究组织(IOIBD)治疗靶点选择更新:确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
10
Effects of 5-aminosalicylates or thiopurines on the progression of low-grade dysplasia in patients with inflammatory bowel disease: a systematic review and meta-analysis.5-氨基水杨酸或硫嘌呤类药物对炎症性肠病患者低级别异型增生进展的影响:系统评价和荟萃分析。
Int J Colorectal Dis. 2021 Jan;36(1):11-18. doi: 10.1007/s00384-020-03735-3. Epub 2020 Sep 1.

中东欧炎症性肠病护理中的障碍:一项区域特异性分析。

Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis.

作者信息

Prokopič Michal, Gilca-Blanariux Georgiana, Lietava Peter, Trifan Anca, Pietrzak Anna, Ladic Agata, Brinar Marko, Turcan Svetlana, Molnár Tamás, Bánovčin Peter, Lukáš Milan

机构信息

Department of Gastroenterology, Jessenius Faculty of Medicine, Comenius University Bratislava, Kollárova 2, Martin 036 01, Slovakia.

Department of Gastroenterology, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania.

出版信息

Therap Adv Gastroenterol. 2023 Jun 12;16:17562848231174290. doi: 10.1177/17562848231174290. eCollection 2023.

DOI:10.1177/17562848231174290
PMID:37333465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10272651/
Abstract

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic immune-mediated diseases with a high incidence and prevalence in Europe. Since these are diseases with associated disability, they require complex management and the availability of high-quality healthcare resources. We focused on the analysis of IBD care in selected countries of Central and Eastern Europe (Croatia, the Czech Republic, Hungary, Moldova, Poland, Romania and Slovakia) targeting the availability and reimbursement of diagnostic and therapeutic modalities, the role of IBD centers and also education and research in IBD. As part of the analysis, we created a questionnaire of 73 statements organized in three topics: (1) diagnostics, follow-up and screening, (2) medications and (3) IBD centers. The questionnaire was filled out by co-authoring IBD experts from individual countries, and then the answers and comments on the questionnaire were analyzed. We identified that despite the financial burden, which still partially persists in the region, the availability of some of the cost-saving tools (calprotectin test, therapeutic drug monitoring) differs among countries, mainly due to variable reimbursement from country to country. In most participating countries, there also remains a lack of dedicated dietary and psychological counseling, which is often replaced by recommendations offered by gastroenterologists. However, there is adequate availability of most of the currently recommended diagnostic methods and therapies in each participating country, as well as the implementation of established IBD centers in the region.

摘要

炎症性肠病(IBD),包括克罗恩病和溃疡性结肠炎,是欧洲发病率和患病率都很高的慢性免疫介导性疾病。由于这些疾病会导致残疾,因此需要复杂的管理以及优质医疗资源的可及性。我们重点分析了中东欧部分国家(克罗地亚、捷克共和国、匈牙利、摩尔多瓦、波兰、罗马尼亚和斯洛伐克)的IBD护理情况,目标是诊断和治疗方式的可及性与报销情况、IBD中心的作用以及IBD方面的教育与研究。作为分析的一部分,我们编制了一份包含73项陈述的问卷,分为三个主题:(1)诊断、随访与筛查,(2)药物,(3)IBD中心。问卷由来自各个国家的共同撰写的IBD专家填写,然后对问卷的答案和评论进行分析。我们发现,尽管该地区仍部分存在经济负担,但一些节省成本的工具(钙卫蛋白检测、治疗药物监测)的可及性在各国有所不同,主要原因是各国的报销情况不同。在大多数参与国,专门的饮食和心理咨询也仍然缺乏,这往往由胃肠病学家提供的建议所取代。然而,每个参与国目前推荐的大多数诊断方法和治疗方法都有足够的可及性,该地区也建立了IBD中心。